OPTINOSE
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high d... ose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.
OPTINOSE
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2000-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.optinose.com
Total Employee:
101+
Status:
Active
Contact:
267-364-3500
Total Funding:
401.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aprecia Pharmaceuticals
Aprecia Pharmaceuticals develops precision drug delivery systems and products.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
FGen
FGen develops proprietary technologies and products in different biotechnological areas.
Myomo
Myomo develops devices with myoelectric prosthetic technology to restore the mobility of individuals with muscle weakness.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Current Advisors List
Board_member
2010-01-01
Current Employees Featured
Per Djupesland Founder & CSO @ OptiNose
Founder & CSO
Peter K. Miller CEO @ OptiNose
CEO
Ramy A. Mahmoud COO @ OptiNose
COO
Helena Djupesland Vice President, Business Development @ OptiNose
Vice President, Business Development
2010-06-01
Mike Marino Chief Legal Officer @ OptiNose
Chief Legal Officer
Anthony Krick VP and Chief Accounting Officer @ OptiNose
VP and Chief Accounting Officer
2022-01-01
Victor Clavelli Chief Commercial Officer @ OptiNose
Chief Commercial Officer
2020-02-01
Michele Janis Acting Chief Financial Officer @ OptiNose
Acting Chief Financial Officer
2022-06-01
Founder
Stock Details
Investors List
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - OptiNose
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series D - OptiNose
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series D - OptiNose
Entrepreneurs Fund
Entrepreneurs Fund investment in Series D - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series C - OptiNose
The Entrepreneurs' Fund
The Entrepreneurs' Fund investment in Series C - OptiNose
WFD Ventures
WFD Ventures investment in Series C - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series C - OptiNose
Entrepreneurs Fund
Entrepreneurs Fund investment in Series C - OptiNose
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-03 | Optinose Announces Departure of Chief Financial Officer |
Official Site Inspections
http://www.optinose.com Semrush global rank: 2.7 M Semrush visits lastest month: 6.13 K
- Host name: 20.119.8.33
- IP address: 20.119.8.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "OptiNose"
Leadership Team - Optinose
Our Company - Optinose
Our Company Optinose is a specialty pharmaceutical company focused on the development and commercialization of products for patients cared for by, or in consultation with, ear, nose, and …See details»
Optinose - LinkedIn
Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts.See details»
OptiNose - Crunchbase Company Profile & Funding
OptiNose is a pharmaceutical company that develops and commercializes treatments for ear, nose, and throat (ENT) disorders.See details»
Investors | Optinose
The Investor Relations website contains information about Optinose's business for stockholders, potential investors, and financial analysts.See details»
Optinose Company Profile | Management and Employees List
Optinose Profile and History Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose …See details»
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant ...
BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive …See details»
OptiNose Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 OptiNose has 4 employees across 3 locations and $70.99 m in annual revenue in FY 2023. See insights on OptiNose including office locations, competitors, revenue, financials, …See details»
OptiNose, Inc. (OPTN) Company Profile & Facts - Yahoo Finance
See the company profile for OptiNose, Inc. (OPTN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Optinose Reports 2024 Financial Results, Highlights Prescription
YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced its financial results for the year and quarter ending December 31, 2024, spotlighting strong growth in XHANCE prescriptions …See details»
OptiNose, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore OptiNose, Inc. with its drug pipeline, therapeutic area, technology platform, 19 clinical trials, 82 news, and 17 literature, Disease Domain:Infectious ...See details»
Form 8-K for Optinose INC filed 03/20/2025
Mar 20, 2025 Optinose and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Optinose in connection with the proposed …See details»
Optinose Reports Fourth Quarter and Full Year 2024 ... - Morningstar
2 days ago About Optinose Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.See details»
Our Purpose - Optinose
Optinose is a specialty pharmaceutical company dedicated to using breakthrough technology to improve patient treatments in areas of substantial ongoing need.See details»
OptiNose - Funding, Financials, Valuation & Investors
OptiNose is a pharmaceutical company that develops and commercializes treatments for ear, nose, and throat (ENT) disorders.See details»
Optinose - Overview, News & Similar companies | ZoomInfo.com
May 16, 2024 View Optinose (www.optinose.com) location in Pennsylvania, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Paratek Pharmaceuticals to acquire Optinose in $330M transaction
Mar 20, 2025 Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, …See details»
OptiNose Inc. Q4 Loss Decreases, Beats Estimates - Nasdaq
2 days ago (RTTNews) - OptiNose Inc. (OPTN) revealed Loss for fourth quarter that decreased from last year and beat the Street estimates. The company's bottom line came in at -$0.36 …See details»
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant ...
Mar 20, 2025 Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑mill...See details»
OptiNose Q4 Net Loss Narrows - Nasdaq
2 days ago (RTTNews) - OptiNose, Inc. (OPTN), a pharmaceutical company, on Wednesday that its net loss narrowed in the fourth quarter compared with the last year. In the fourth …See details»